Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
RxSight (NASDAQ: RXST) reported preliminary Q4 2024 revenue of $40.2 million, up 41% year-over-year, driven by sales of 29,069 Light Adjustable Lenses (LAL™/LAL+®) and 83 Light Delivery Devices (LDD™s). The company’s installed base reached 971 LDDs, a 46% increase from Q4 2023.
Full-year 2024 revenue is expected at $139.9 million, representing 57% growth, with 98,055 LALs sold and 305 LDDs installed. The company now serves approximately 15% of North American cataract surgeons, with LAL procedures representing over 10% of the region’s premium IOL market.
For 2025, RxSight projects revenue between $185.0-197.0 million (32-41% growth), with gross profit margins of 71-73% and operating expenses of $165.0-170.0 million. Cash position as of December 31, 2024, was $237.2 million.
RxSight (NASDAQ: RXST) ha riportato un fatturato preliminare per il quarto trimestre del 2024 di 40,2 milioni di dollari, in aumento del 41% rispetto all’anno precedente, grazie alle vendite di 29.069 Lenti Regolabili in Luce (LAL™/LAL+®) e 83 Dispositivi di Somministrazione della Luce (LDD™s). Il numero di LDD installati dalla società ha raggiunto 971, con un incremento del 46% rispetto al quarto trimestre del 2023.
Il fatturato totale per il 2024 è previsto a 139,9 milioni di dollari, con una crescita del 57%, avendo venduto 98.055 LAL e installato 305 LDD. Attualmente, l’azienda serve circa il 15% dei chirurghi della cataratta in Nord America, con le procedure LAL che rappresentano oltre il 10% del mercato premium delle IOL nella regione.
Per il 2025, RxSight prevede un fatturato compreso tra 185,0 e 197,0 milioni di dollari (crescita del 32-41%), con un margine di profitto lordo del 71-73% e spese operative tra 165,0 e 170,0 milioni di dollari. La posizione di liquidità al 31 dicembre 2024 era di 237,2 milioni di dollari.
RxSight (NASDAQ: RXST) reportó ingresos preliminares para el cuarto trimestre de 2024 de $40.2 millones, un incremento del 41% interanual, impulsado por las ventas de 29,069 Lentes Ajustables a la Luz (LAL™/LAL+®) y 83 Dispositivos de Entrega de Luz (LDD™s). La base instalada de la compañía alcanzó 971 LDDs, un aumento del 46% respecto al cuarto trimestre de 2023.
Se espera que los ingresos para todo el año 2024 sean de $139.9 millones, lo que representa un crecimiento del 57%, con 98,055 LAL vendidos y 305 LDD instalados. La compañía ahora atiende aproximadamente al 15% de los cirujanos de cataratas en América del Norte, con los procedimientos de LAL representando más del 10% del mercado de IOL premium en la región.
Para 2025, RxSight proyecta ingresos entre $185.0 y $197.0 millones (crecimiento del 32-41%), con márgenes de ganancia bruta del 71-73% y gastos operativos de entre $165.0 y $170.0 millones. La posición de efectivo al 31 de diciembre de 2024 era de $237.2 millones.
RxSight (NASDAQ: RXST)는 2024년 4분기 예상 수익이 4,020만 달러였으며, 이는 전년 대비 41% 증가한 수치라고 보고했습니다. 이는 29,069개의 조정 가능한 광학 렌즈(LAL™/LAL+®)와 83개의 광 전달 장치(LDD™s)의 판매에 의해 주도되었습니다. 회사의 설치된 LDD 수는 971개에 도달했으며, 이는 2023년 4분기 대비 46% 증가한 수치입니다.
2024년 전체 수익은 1억 3,990만 달러로 예상되며, 이는 57% 성장에 해당하고, 판매된 LAL 수는 98,055개, 설치된 LDD 수는 305개입니다. 현재 회사는 북미의 15%에 해당하는 백내장 수술 의사를 지원하고 있으며, LAL 시술은 해당 지역의 프리미엄 IOL 시장의 10% 이상을 차지하고 있습니다.
2025년을 위해 RxSight는 수익을 1억 8,500만 달러에서 1억 9,700만 달러로 예상하고 있으며(32-41% 성장), 총 이익률은 71-73%, 운영 비용은 1억 6,500만 달러에서 1억 7,000만 달러로 예상하고 있습니다. 2024년 12월 31일 기준 현금 보유액은 2억 3,720만 달러였습니다.
RxSight (NASDAQ: RXST) a enregistré des revenus préliminaires pour le quatrième trimestre 2024 s’élevant à 40,2 millions de dollars, en hausse de 41 % par rapport à l’année précédente, grâce à la vente de 29 069 Lentilles Réglables à Lumière (LAL™/LAL+®) et de 83 Dispositifs de Livraison de Lumière (LDD™s). La base installée de l’entreprise a atteint 971 LDD, soit une augmentation de 46 % par rapport au quatrième trimestre 2023.
Les revenus annuels pour 2024 devraient s’élever à 139,9 millions de dollars, ce qui représente une croissance de 57 %, avec 98 055 LAL vendues et 305 LDD installés. L’entreprise dessert désormais environ 15 % des chirurgiens de la cataracte en Amérique du Nord, les procédures LAL représentant plus de 10 % du marché des IOL premium dans la région.
Pour 2025, RxSight prévoit des revenus compris entre 185,0 et 197,0 millions de dollars (croissance de 32 à 41 %), avec des marges bénéficiaires brutes de 71 à 73 % et des dépenses opérationnelles de 165,0 à 170,0 millions de dollars. La position de trésorerie au 31 décembre 2024 s’élevait à 237,2 millions de dollars.
RxSight (NASDAQ: RXST) meldete vorläufige Einnahmen für das vierte Quartal 2024 in Höhe von 40,2 Millionen US-Dollar, was einem Anstieg von 41% im Jahresvergleich entspricht, bedingt durch den Verkauf von 29.069 Lichtverstellbaren Linsen (LAL™/LAL+®) und 83 Lichtliefergeräten (LDD™s). Der installierte Bestand des Unternehmens erreichte 971 LDDs, ein Anstieg von 46% im Vergleich zum vierten Quartal 2023.
Für das Gesamtjahr 2024 wird ein Umsatz von 139,9 Millionen US-Dollar erwartet, was einem Wachstum von 57% entspricht, wobei 98.055 LAL verkauft und 305 LDD installiert wurden. Das Unternehmen bedient jetzt etwa 15% der Kataraktchirurgen in Nordamerika, wobei LAL-Verfahren über 10% des Premium-IOL-Marktes in der Region ausmachen.
Für 2025 rechnet RxSight mit Einnahmen zwischen 185,0 und 197,0 Millionen US-Dollar (32-41% Wachstum), mit Bruttogewinnmargen von 71-73% und Betriebskosten von 165,0-170,0 Millionen US-Dollar. Die Liquiditätsposition am 31. Dezember 2024 betrug 237,2 Millionen US-Dollar.
Positive
- Q4 2024 revenue grew 41% YoY to $40.2 million
- Full-year 2024 revenue increased 57% to $139.9 million
- LAL procedure volume grew 79% in 2024
- Installed base expanded 46% YoY to 971 LDDs
- Strong cash position of $237.2 million
- Projected 32-41% revenue growth for 2025
- High gross profit margin guidance of 71-73% for 2025
Negative
- Significant operating expenses projected for 2025 ($165-170 million)
- Final results subject to audit completion
Insights
The preliminary Q4 results showcase exceptional performance with revenue reaching $40.2M, marking a 41% YoY growth. The full-year revenue of $139.9M significantly outperformed initial guidance, driven by robust LAL sales growth of 79%. The healthy cash position of $237.2M provides substantial runway for expansion plans.
The market penetration metrics are particularly impressive – capturing 15% of North American cataract surgeons and 10% of the premium IOL market. The projected 2025 revenue guidance of $185-197M implies continued strong growth of 32-41%, while the anticipated gross margin of 71-73% indicates operational efficiency and pricing power.
The projected operating expenses of $165-170M for 2025 suggest significant investment in growth initiatives, including international expansion and product innovation. While this may impact near-term profitability, it positions the company for sustained long-term growth in the premium ophthalmology market.
The accelerating adoption of the RxSight system reflects a paradigm shift in cataract surgery outcomes. The installation of 971 LDDs represents critical mass achievement, creating a network effect that could drive faster market penetration. The 61% increase in LAL procedures indicates strong surgeon confidence and patient satisfaction.
The planned expansion into Asian and European markets presents significant growth potential, given the aging demographics and higher cataract surgery volumes in these regions. The company’s focus on innovation and system improvements suggests a strategic approach to maintaining technological leadership in the premium IOL segment.
In simple terms: Think of this like a high-tech adjustable lens that’s quickly becoming the preferred choice for eye surgeons. The company has installed nearly 1,000 special machines that allow doctors to fine-tune these lenses after surgery, leading to better vision outcomes for patients. They’re now planning to take this technology global while continuing to make it even better.
ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) — (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2024 and provided full-year 2025 guidance.
Preliminary Unaudited Fourth Quarter and Full-year 2024 Results
- Preliminary unaudited fourth quarter 2024 revenue is expected to be approximately $40.2 million, representing growth of approximately 41% compared to the prior year period, driven by:
- The sale of 29,069 Light Adjustable Lenses (LAL™/LAL+®); representing a 61% increase in procedure volume compared to the fourth quarter of 2023; and
- The sale of 83 Light Delivery Devices (LDD™s), expanding the installed base to 971 LDDs as of December 31, 2024, representing a 46% increase compared to the installed base at end of the fourth quarter of 2023.
- Preliminary unaudited 2024 fiscal year revenue is expected to be approximately $139.9 million, representing growth of approximately 57% compared to the prior year, driven by:
- The sale of 98,055 LALs; representing a 79% increase in procedure volume compared to 2023; and
- The sale of 305 LDDs.
- Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2024, is expected to be $237.2 million.
“During the fourth quarter, we achieved record highs for LDD sales and LAL procedures, meaningfully exceeding our initial full-year 2024 revenue guidance. With nearly one thousand LDDs installed, we now serve an estimated 15% of cataract surgeons in North America, while LAL procedures account for over 10% of the region’s premium IOL market. We believe this sustained growth in one of ophthalmology’s most competitive segments reflects the growing recognition of the superior visual outcomes enabled by adjustability,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. “In 2025, we expect adoption for the RxSight system to remain strong as we collaborate with a diverse range of customers to further expand the infrastructure for post-operative light treatments. Building on our momentum in North America, we also look forward to entering key international markets in Asia and Europe. Finally, leveraging the foundation established since our initial FDA approval, we plan to continue to innovate the RxSight system, that we believe will continue to set the standard for the premium IOL market for years to come.”
2025 Guidance
RxSight anticipates full-year 2025 revenue in the range of $185.0 million to $197.0 million, reflecting growth of approximately 32% to 41% over 2024. The company currently estimates the full-year 2025 gross profit margin to be in the 71% to 73% range. In addition, the company expects full-year 2025 operating expenses in the range of $165.0 million to $170.0 million, including non-cash stock-based compensation expense guidance in the range of $22.0 million to $25.0 million.
The Company’s fourth quarter and full-year 2024 financial and operational results are preliminary and are subject to the completion of the Company’s 2024 audit. Audited full-year 2024 and unaudited fourth quarter 2024 financial results are expected to be announced in February 2025.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Forward-Looking Statements
This press release contains forward-looking statements, including: statements concerning: the growing recognition of superior outcomes enabled by adjustability; the Company’s preliminary unaudited fourth quarter and fiscal 2024 financial and operational results and the anticipated timing of announcing audited full-year 2024 and unaudited fourth quarter 2024 financial results; the expectation of strong adoption for the RxSight system; the Company’s plans to enter international markets; the Company’s plans to continue innovating the RxSight system, that it believes will set the standard for the premium IOL market for the years to come; the potential of the Company’s technology and management’s plans related thereto; and the Company’s projected revenue, gross profit margin, operating expenses and non-cash expenses in 2025. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, including those risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including in Part II, Item 1A (Risk Factors) of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 7, 2024, and any subsequent filings with the SEC. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
The foregoing financial and operational results are preliminary estimates. We are in the process of finalizing our financial statements for the year ended December 31, 2024, and our actual results remain subject to completion of those financial statements and their audit by our independent registered public accounting firm. These preliminary estimates are based on information available to management as of the date of this press release and certain related assumptions, which could prove incorrect. Our actual, reported results of operations could differ based on completion of our year end closing procedures, final adjustments and developments that may arise prior to completion of our annual financial statements, and adjustments arising from the audit by our independent registered public accounting firm. You should carefully review our audited, consolidated financial statements for the year ended December 31, 2024 when they become available.
Company contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
FAQ
What was RxSight’s (RXST) revenue growth in Q4 2024?
RxSight’s Q4 2024 revenue grew 41% year-over-year to $40.2 million.
How many Light Adjustable Lenses (LAL) did RXST sell in 2024?
RxSight sold 98,055 Light Adjustable Lenses in 2024, representing a 79% increase from 2023.
What is RXST’s revenue guidance for 2025?
RxSight projects 2025 revenue between $185.0-197.0 million, representing 32-41% growth over 2024.
What was RxSight’s (RXST) market penetration in North America by end of 2024?
RxSight served approximately 15% of North American cataract surgeons, with LAL procedures representing over 10% of the region’s premium IOL market.
What is RXST’s projected gross profit margin for 2025?
RxSight expects a gross profit margin between 71-73% for 2025.
